Immunicom’s Immunopheresis™ is designed to empower patients to best live their lives while receiving revolutionary cancer treatment.
Location: United States, California, San Diego
Total raised: $12.85M
Investors 1
| Date | Name | Website |
| - | Bootstrap ... | bootstrapv... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.10.2019 | Series B | $1.85M | - |
| 02.07.2019 | Series B | $11M | - |
Mentions in press and media 6
| Date | Title | Description |
| 17.11.2021 | Terumo Blood and Cell Technologies and Immunicom Establish Agreement to Launch Breakthrough Cancer Immunotherapy Treatment in Europe | The therapy aims to re-energize a patient's immune system to fight cancer tumors Initial commercialization will target leading oncology centers in Germany, France, Italy, and Spain LAKEWOOD, Colo. and SAN DIEGO, Nov. 17, 2021 /PRNewswire/ -... |
| 13.09.2021 | Zoom Video Communications : 2021 Zoomtopia Innovation Award Winners | Customer Stories, Zoomtopia 2021 Zoomtopia Innovation Award Winners Zoom September 13, 20215 min read We're so excited to bring you the Zoomtopia Innovations Awards at this year's Zoomtopia, where we highlight inspiring and innovative ways ... |
| 23.03.2021 | Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC) | SAN DIEGO--(BUSINESS WIRE)--Mar 23, 2021-- Immunicom, Inc., a global biotechnology company pioneering novel “subtractive” immunotherapies, today announced that the Immunopheresis™ LW-02 blood-filtering column, its leading immuno-oncology pr... |
| 01.10.2019 | Immunicom Secures Additional $1.85M Bringing Series B to $12.85M | Immunicom, Inc., a San Diego, CA-based medical technology company providing a non-pharmaceutical solution for treating stage IV metastatic cancer, raised an additional $1.85m towards its Series B investment round. This increases Series B ro... |
| 03.07.2019 | Immunicom raises $11M for cancer treatment device | Biotech company Immunicom, which has developed a non-pharmaceutical, late-stage cancer treatment, has raised $11 million in a Series B investment round. Several private equity family offices participated in the round, increasing Immunicom’s... |
| 02.07.2019 | Immunicom Raises $11M in Series B Funding | Immunicom, Inc., a San Diego, CA-based biotechnology company focused on advancing a non-pharmaceutical solution for treating late-stage metastatic cancer, raised $11m in Series B funding. Several private equity family offices participated i... |